Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma.
We report the results of rituximab monotherapy in 21 patients with refractory or relapsed aggressive non Hodgkin s lymphoma (NHL). The majority of the patients (16/21) were refractory to conventional treatment and not eligible for high dose chemotherapy. Responses (1 complete and 6 partial) were achieved in some of these patients and their median overall survival was 8 months.